Welcome on the Necker-Enfants Malades Institute website
  • Glomerular endothelial cell senescence drives age-related kidney disease through PAI-1

    A study conducted by the team of Fabiola Terzi has just been published in EMBO Molecular Medicine :

  • Jean-Claude Weill participe à la table ronde "Pourquoi la recherche est-elle malmenée en France ?"
    «Redonner à la recherche fondamentale ses lettres de noblesse, qui, sur le long terme, sans être tournée vers telle ou telle application, a été rien qu’en biologie médicale à l’origine des plus grands brevets, estimés souvent à plusieurs centaines de milliards.
    Jean-Claude Weill, professeur émérite à l’Institut Necker Enfants Malades et membre de [...]
  • De nouvelles perspectives thérapeutiques pour les patients porteurs d’anomalies lymphatiques liées à une mutation du gène PIK3CA

    Une étude menée par le Pr Guillaume Canaud, médecin à l’Hôpital Necker Enfants Malades et Directeur de Laboratoire à l’Institut Necker Enfants [...]

  • New therapeutic perspectives for patients with lymphatic anomalies linked to a PIK3CA gene mutation

    A study conducted by Prof. Guillaume Canaud, physician at the Necker Enfants Malades Hospital and Laboratory Director at the Necker Enfants Malades Institute has just been published in the journal Science Translational Medicine

    This team created a mouse model that develops lymphatic anomalies linked to the PIK3CA gene mutation similar to those of patients. The team then [...]

  • La revalorisation de la recherche publique : tribune par Jean-Claude Weill
    « La situation de la recherche publique en France se heurte à un problème qui échappe totalement aux instances dirigeantes : l’attractivité des métiers de la recherche. » Jean-Claude Weill, professeur émérite à l’Institut Necker Enfants Malades et membre de l’Académie de Sciences, signe une [...]
  • La vaccination pour les débutants
    Claude-Agnès Reynaud, directeur de recherche au CNRS et Jean-Claude Weill, professeur d’immunologie à l’Université de Paris, des spécialistes reconnus dans le domaine de l’immunité présentent l’état de nos connaissances concernent la réponse immunitaire aux vaccins anti-covid, et pour le comprendre, expliquent les [...]
The Institute
The Institut Necker-Enfants Malades (INEM), created in January 2014, is an international biomedical research center located on the Necker Hospital campus, and supported by the French National Institute of Health and Medical Research (INSERM), the French National Center for Scientific Research (CNRS) and the University of Paris.

Research at INEM is focusing on common diseases caused by the interplay of polygenic inheritance and environmental factors. These diseases primarily affect children and the young, and encompass (auto)immune disorders, haematological diseases, infectious diseases, kidney diseases, cystic fibrosis, endocrinological disorders and metabolic diseases. The INEM teams apply insights obtained through basic and clinical research to develop innovative diagnostic and therapeutic strategies.

For over 40 years, the development of renal transplants and bone marrow transplants, the phenotyping of autoimmune diseases and genetic diseases, allowed most of the major medical advances of today. The major asset of the Institute Necker-Enfants Malades comes from the plurality of skills, the freedom and creativity of its researchers, their desire to diversify their research topics.

Translational activities will be pursued and promoted as much as possible. Indeed, this group of PIs has filed 24 patents, 4 of which are licenced to pharmaceutical companies. 13 R&D contracts have been signed with industry and 3 start-up companies incorporated with one of the above PIs as founder. To further strengthen the link with the socio-economic world, we intend to devote one floor of our research building to hosting private entities, either small companies or teams from bigger pharmaceutical industries wishing to collaborate with groups of the Necker-Enfants Malades Institute.

Our mission

The close interaction between the research labs and the clinical departments is one of our major strengths creating a highly dynamic environment and promoting translational and “bench to bedside” activities. Our research programs are consistent with this mission and most groups have very tight connections with the clinics, mostly through clinicians with joint appointments in research labs and clinical departments.

Our research in the coming years will focus on:
  • Understanding the molecular mechanisms of leukemia is to use targeted therapies and avoid chemotherapy whose collateral damage is known
  • Defeating diabetes, especially the type 1 in children (440,000 in the world), is to address the treatment of autoimmune diseases, more and more frequent in developed countries, as the case for multiple sclerosis or lupus.
  • Succeed one day to control the immune system, thanks to the long experience and considerable clinical material at the Necker hospital on kidney and bone marrow transplantations, is a priority
  • Seek to determine the mechanisms responsible for bacterial meningitis, debilitating in a few hours a perfectly healthy child or subject, is essential to develop effective and safe vaccines.
  • Apply our knowledge of metabolism and growth to promote innovative and personalized therapies in the field of kidney disease, diabetes, cystic fibrosis, muscular dystrophy and various solid tumors.
The Necker-Enfants Malades Institute is administered by one Director assisted by the two department Heads and one General secretary in charge the administration. Each PI or CoPI is responsible for his (her) scientific project and for the use of his (her) allocated space
Fabiola Terzi
INEM Director
Mario Pende
Marco Pontoglio
Director of "Growth and Signalling" Dept
Peter Van Endert
Simon Fillatreau
Director of "Immunology, Infectiology and Haematology" (I2H) Dept
Sophie Koutouzov
General Secretary
The scientific teams
The people of INEM

Thirteen research teams are founding members of the Necker-Enfants Malades Institute, which comprises today 19 research teams. The teams are grouped in two departments: a department of cell biology (Growth and Signalling) and a department of, Immunology, Infectiology and Haematology (I2H).

The Necker-Enfants Malades Institute currently comprises 103 senior scientists, one third of whom are medical doctors, 60 technicians and engineers, 35 postdoctoral fellows and 37 PhD students. Among the 19 teams, 7 have already obtained an award from the European Research Council.

Contact us
+33 (0)1 40 61 53 00
Institut Necker Enfants Malades

Faculté de Médecine Necker
160, rue de Vaugirard
75015 Paris Cedex
HRH Princess Caroline of Hanover, who through the Princess Grace Foundation, already supports medical research and anything that helps to relieve the sick children in France and around the world, has agreed to commit to our side so that our Center of Molecular medicine continues to meet the current challenges and fight diseases, and in particular the ones affecting children.

INEM - Organigramme